An interventional study of VI-RASD use in minimally invasive right or left colectomy and Right or Left colectomy in Colon Cancer, Colon Polyp and Diverticular Diseases, sponsored by Virtual Incision Corporation. Active, not recruiting at 3 sites in United States. Open to participants aged 22 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Virtual Incision Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,123 studies in Colonic Neoplasms with a site in United States — 115 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.
Among the 1,123 studies in Colonic Neoplasms with a site in United States, this one is the 550th largest by enrollment of the 865 interventional ones that give a count, is one of 40 that started in 2021, is one of 264 with no phase, reaches primary completion later than 7 of the 187 other live ones, and was the 908th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.
Browse Colonic Neoplasms studies →115 of the 1,123 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Puerto Rico
Ages 18+
Solstice Oncology, Inc. · Sites in United States, Belgium, Italy and 3 more countries
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
Guardant Health, Inc. · Sites in United States
Ages 45–75 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 22 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,123 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 341 · Phase 3 87 · Phase 4 10
First in 1981; this study’s year is marked. 40 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 75 across 1,711 interventional studies indexed under Colonic Neoplasms.
Median enrollment 50 across the 865 interventional studies, 220 across the 181 observational. Of the 840 that completed or were terminated, 241 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
229 of 1,123 have an industry lead sponsor. The 10 most frequent:
Virtual Incision Corporation is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Virtual Incision Corporation has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
60 of the studies in Colonic Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03803553Phase 3Massachusetts General HospitalIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | 2026-12 |
| NCT06191185University of California, San FranciscoIMProving Adherence to Colonoscopy Through Teams and Technology | 2026-11-27 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
| NCT00582621Memorial Sloan Kettering Cancer CenterAscertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders | 2026-12 |
Add all 60 to your calendar (.ics) → With an account.
Among the 1,123 studies in Colonic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
For patients with colon polyps (clumps of cells in the lining of the colon) treatment often requires removal of the affected portion of the colon. Both conventional laparoscopic and robotically assisted minimally invasive surgery have been shown to have reduced complication rates and shorter hospital stays.
This study aims to look at the use of the VI RASD as a robotic surgical device in right or left colectomy procedures to see if the device performs as intended and is safe for use.
The purpose of the clinical study is to evaluate the device's indications for use in the clinical environment. The VI RASD is a surgical tool intended to assist in the endoscopic manipulation of tissue during bowel resections. The VI RASD is designed to allow a surgeon to perform minimally invasive colon procedures in the same fashion used in laproscopic and robotically assisted surgery with a single incision site in the abdominal wall.
The study will evaluate the efficacy of the VI RASD in manipulating and dissecting the right or left colon and preparing the colon for resection. The safety profile of the device will also be assessed through analysis of overall intraoperative and post operative adverse events as compared to published literature.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of VI RASD in right or left colectomy procedures
Device: VI-RASD use in minimally invasive right or left colectomy · Procedure: Right or Left colectomy
Virtual Incision Corp, VI-RASD use in right or left colectomy procedures.
Surgical Procedures in which the VI RASD will be used.
Efficacy: Number of Participants With Successful Completion of the VI RASD Steps in Colectomy Procedures Without Conversion to Open Surgery
Count and calculated percentage of enrolled subjects in which the VI RASD steps were successfully completed and did not require conversion to open surgery. VI RASD steps include: the VI-RASD system is inserted and deployed to corresponding abdominal cavity, used to manipulate and dissect the colon allowing for transection of the colon and small bowel, and system is removed from the abdominal cavity.
Time frame: Intraoperative Period- Surgical Procedure Start time to Surgical Procedure End time
Determine the Safety Profile of VI-RASD as the Number of Enrolled Subjects Experiencing Either an Intraoperative and/or Postoperative Adverse Events Occurring Within 30 Days Post Procedure.
Count and calculated percentage of enrolled subjects experiencing an intraoperative and/or postoperative adverse events.
Time frame: Time insertion of the VI RASD device is initiated (intraoperative) through 30 days (+/- 5 days) post procedure (post operative).
Clinical Outcome Measure- Length of Stay (Number of Days)
Median number of days for the VI-RASD arm calculated from Date of Procedure (Day 0) to Date of Discharge.
Time frame: Calculated in number of days from date of procedure through date of discharge
Clinical Outcome Measures-Number of Subjects With Reported Intraoperative Adverse Event
Comparison of number/calculated percentage of enrolled subjects experiencing an intraoperative adverse event.
Time frame: Intraoperative-Procedure start time to Procedure end time
Clinical Outcome Measure- Number of Participants Requiring Conversion to Open Surgery
Count and calculated percentage of enrolled subjects requiring conversion to open surgery.
Time frame: Intraoperative: Procedure start time to Procedure end time
Clinical Outcome Measure-Median Operative Time for All Enrolled Participants.
Median time(all enrolled participants) in minutes elapsed between procedure start and stop time.
Time frame: Intraoperative: Procedure Start Time to Procedure End Time
Clinical Outcome Measure-Number of Subjects With Reported Post Operative Complications Related to Study Device and/or Procedure.
Comparison of Number/Calculated percentage of participants with a reported adverse event related to the study device and/or procedure that occurred post operatively thru the 30 day post procedure visit.
Time frame: Procedure end time thru 30 day post procedure visit
Clinical Outcome Measure-Re-admission Rate: Number of Participants Readmitted to Hospital
Number/calculated percentage of participants readmitted to the hospital after discharge from study procedure for any reason.
Time frame: From date of discharge thru 30 days post procedure
Clinical Outcome Measure- Re Encounter Rates-Number of Participants Requiring an Unplanned Visit.
Number/Calculated Percentage of participants requiring an unplanned follow up visit for a potential complication related to procedure. Unplanned visit defined as either a phone call with medical provider or a visit to a medical provider.
Time frame: From date of discharge thru 30 days post procedure
Clinical Outcome Measure-Reoperation Rate: Number of Participants Requiring Reoperation
Total number/calculated percentage of subjects requiring any additional operation related to the underlying medical condition. This number is compared to Published literature Zawadski PMID 31481637
Time frame: From date of procedure thru 30 day post procedure.
Clinical Outcome Measure-Reoccurrence Rate: Number of Participants With Recurrence of Disease
Number of subjects reporting recurrence of underlying medical condition/indication for for colectomy procedure. No comparative data is available in published literature referenced in the study.
Time frame: From date of procedure thru 30 days post procedure.
Clinical Outcome Measure- Mortality: Number of Deaths Reported
Number and calculated percentage of all cause deaths.
Time frame: From date of procedure through 30 day post procedure
Clinical Outcome Measure- Number of Additional Laparoscopic Ports Used, Including Reason for Use.
Number of additional laparoscopic ports used during procedure was collected. Reason for additional port also captured.
Time frame: Intraoperative
Long Term Oncological Status
Annual assessment of cancer status (Active-with/without treatment, metastasized, remission).
Time frame: Date of procedure through 5 years post procedure
| Milestone | VI-RASD |
|---|---|
| Started | 30 |
| Completed | 30 |
| Not completed | 0 |
Count and calculated percentage of enrolled subjects in which the VI RASD steps were successfully completed and did not require conversion to open surgery. VI RASD steps include: the VI-RASD system is inserted and deployed to corresponding abdominal cavity, used to manipulate and dissect the colon allowing for transection of the colon and small bowel, and system is removed from the abdominal cavity.
| Participants | VI-RASD |
|---|---|
| Primary dissection completed with VI RASD | 30 |
| Conversion to Open surgery | 0 |
Count and calculated percentage of enrolled subjects experiencing an intraoperative and/or postoperative adverse events.
| Participants | VI-RASD |
|---|---|
| Intraoperative complications | 0 |
| Post operative complications | 10 |
Median number of days for the VI-RASD arm calculated from Date of Procedure (Day 0) to Date of Discharge.
| Days | VI-RASD |
|---|---|
| Clinical Outcome Measure- Length of Stay (Number of Days) | 3.6 (2 to 26) |
Comparison of number/calculated percentage of enrolled subjects experiencing an intraoperative adverse event.
| Participants | VI-RASD |
|---|---|
| Device Related | 0 |
| Procedure Related | 0 |
Count and calculated percentage of enrolled subjects requiring conversion to open surgery.
| Participants | VI-RASD |
|---|---|
| Clinical Outcome Measure- Number of Participants Requiring Conversion to Open Surgery | 0 |
Median time(all enrolled participants) in minutes elapsed between procedure start and stop time.
| minutes | VI-RASD |
|---|---|
| Clinical Outcome Measure-Median Operative Time for All Enrolled Participants. | 146 (80 to 309) |
Comparison of Number/Calculated percentage of participants with a reported adverse event related to the study device and/or procedure that occurred post operatively thru the 30 day post procedure visit.
| Participants | VI-RASD |
|---|---|
| Clinical Outcome Measure-Number of Subjects With Reported Post Operative Complications Related to Study Device and/or Procedure. | 10 |
Number/calculated percentage of participants readmitted to the hospital after discharge from study procedure for any reason.
| Participants | VI-RASD |
|---|---|
| Clinical Outcome Measure-Re-admission Rate: Number of Participants Readmitted to Hospital | 0 |
Number/Calculated Percentage of participants requiring an unplanned follow up visit for a potential complication related to procedure. Unplanned visit defined as either a phone call with medical provider or a visit to a medical provider.
| Participants | VI-RASD |
|---|---|
| Clinical Outcome Measure- Re Encounter Rates-Number of Participants Requiring an Unplanned Visit. | 5 |
Total number/calculated percentage of subjects requiring any additional operation related to the underlying medical condition. This number is compared to Published literature Zawadski PMID 31481637
| Participants | VI-RASD | Published Literature: Zawadzki |
|---|---|---|
| Clinical Outcome Measure-Reoperation Rate: Number of Participants Requiring Reoperation | 1 | 51 |
Number of subjects reporting recurrence of underlying medical condition/indication for for colectomy procedure. No comparative data is available in published literature referenced in the study.
| Participants | VI-RASD |
|---|---|
| Clinical Outcome Measure-Reoccurrence Rate: Number of Participants With Recurrence of Disease | 0 |
Number and calculated percentage of all cause deaths.
| Participants | VI-RASD |
|---|---|
| Clinical Outcome Measure- Mortality: Number of Deaths Reported | 0 |
Number of additional laparoscopic ports used during procedure was collected. Reason for additional port also captured.
| number of participants | VI-RASD |
|---|---|
| Requiring one additional port | 19 |
| Requiring two additional ports | 11 |
| Requiring 3 additional ports | 0 |
| Reason for additional port:additional tools | 30 |
| Reason for additional port : Insufflation | 2 |
Annual assessment of cancer status (Active-with/without treatment, metastasized, remission).
Results for this outcome have not been posted.
Collected over Time insertion of the VI RASD device is initiated through 30 days post procedure, approximately one month.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VI-RASD-EXPECTED EVENTS | 0/30 (0%) | 3/30 (10%) | 30/30 (100%) |
| VI RASD -UNEXPECTED EVENTS | 0/30 (0%) | 0/30 (0%) | 0/30 (0%) |
| Event | VI-RASD-EXPECTED EVENTS | VI RASD -UNEXPECTED EVENTS |
|---|---|---|
| Anastomotic haemorrhageInjury, poisoning and procedural complications | 1/30 | — |
| AnemiaBlood and lymphatic system disorders | 1/30 | — |
| Blood Loss AnemiaVascular disorders | 1/30 | — |
| Pelvic AbcessInfections and infestations | 1/30 | — |
| Gastointestinal Anastomotic LeakGastrointestinal disorders | 1/30 | — |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 1/30 | — |
| Septic ShockVascular disorders | 1/30 | — |
| Event | VI-RASD-EXPECTED EVENTS | VI RASD -UNEXPECTED EVENTS |
|---|---|---|
| Incision site painGeneral disorders | 20/30 | — |
| Procedural PainGeneral disorders | 10/30 | — |
| RashSkin and subcutaneous tissue disorders | 2/30 | — |
Subjects undergoing Colectomy procedures using the VI-RASD.
| Age, Categorical(Participants) | VI-RASD |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 17 |
| >=65 years | 13 |
| Age, Continuous(years) | VI-RASD |
|---|---|
| Mean | 59.4 ± 13.4 |
| Sex: Female, Male(Participants) | VI-RASD |
|---|---|
| Female | 13 |
| Male | 17 |
| Race (NIH/OMB)(Participants) | VI-RASD |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 28 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | VI-RASD |
|---|---|
| United States | 30 |
| Body Mass Index Classification(Participants) | VI-RASD |
|---|---|
| Normal, 18.5-24.9 kg/m2 | 9 |
| Overweight, 25.0-29.9 kg/m2 | 13 |
| Obese, ≥30kg/m2 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Feb 2023, 18 months.
Results were first posted in Oct 2026, 3 years 7 months after primary completion. A results delay was requested in Feb 2024.
Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Virtual Incision Corporation